-
How difficult is it to withdraw the "magic drug" from Sharp's eye drops?
Time of Update: 2021-10-10
If 95% of the work is completed, but only 5% short of this point, can I apply for an extension again?According to the official website of the State Food and Drug Administration, the approval date for re-registration of Sharp Aisi eye drops is December 2019.
-
Kanghua Animal Health will open up the "last mile" of rabies prevention
Time of Update: 2021-10-10
"Human use + pet use" high-quality vaccines help promote immunityHow to better respond to the national rabies prevention and control plan and promote the progress of animal immunization, the key lies in the development and production of high-quality animal vaccines .
-
CStone Pharmaceuticals announces CS5001 (ROR1 ADC) research data at the 33rd International Conference on Molecular Targets and Cancer Therapy in 2021
Time of Update: 2021-10-10
Suzhou, China, October 8, 2021/PRNewswire/ - CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focusing on research, development and commercialization o
-
Yuli Pharmaceutical won the 2021 Sustainability Platinum Award from EcoVadis
Time of Update: 2021-10-10
Singapore, October 6, 2021/PRNewswire/ - Zuellig Pharma, Asia's leading healthcare service provider, won the 2021 Platinum Award from EcoVadis, a professional sustainability rating agency .
Our employees provide services to more than 350,000 medical institutions and have established cooperation with more than 1,000 customers, including the world's top 20 pharmaceutical companies .
-
Various places are vigorously promoting the development of the biomedical industry, and this market may usher in a big explosion!
Time of Update: 2021-10-10
In addition to Jiangsu Province, the Hainan Provincial Food and Drug Administration has also issued the "Notice on Further Optimizing Services to Support the High-Quality Development of the Biopharmaceutical Industry", and introduced a total of 12 optimization service measures, from promoting the development of industrial clusters and encouraging the undertaking of the production of pharmaceuticals and medical devices.
-
Nuocheng Jianhua's new drug ICP-723 is selected as one of the 100 new technologies and new products of the Zhongguancun Forum in 2021
Time of Update: 2021-10-10
Beijing, September 29, 2021/PRNewswire/ - Biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) today announced that the company's self-developed second-generation pan-TRK inhibitor ICP-723 has been selected 2021 Zhongguancun International Technology Trade Conference 100 new technologies and new products list .
-
How far is TCM from internationalization?
Time of Update: 2021-10-10
Authors: Liu Shujing, Li ChenshuoThe overseas innovative development of Chinese medicine is an important path to inherit and promote the excellent Chinese traditional culture, and it is also the core
-
Beijing Jishuitan Hospital held the unveiling ceremony of the Wound Repair Center!
Time of Update: 2021-10-10
The scope of diagnosis and treatment of the Burn Plastic Surgery Department and Wound Repair Center mainly includes Treatment of burns of various reasons: large-area severe burns, scalds, explosive compound injuries, inhalation injuries, medium and small-area burns, scalds, frostbite, electric burns, chemical burns (sulfuric acid, hydrochloric acid, aqua regia, caustic soda), heat Treatment of various types of burns such as crush injuries and thermomechanical combined injuries .
-
267 million yuan!
Time of Update: 2021-10-10
For example, on September 28, Innovent announced that it will cooperate with unio therapeutic to discuss unio’s main drug candidate orismilast for the treatment of inflammatory skin diseases, a PDE4 inhibitor in clinical phase II, which has reached an agreement in China (including mainland China).
-
Over 30 new drugs approved in China in the third quarter of 2021!
Time of Update: 2021-10-10
At the same time, a number of new anti-cancer drugs were approved in China for the first time, including the second-generation proteasome inhibitor carfilzomib jointly developed by Amgen and BeiGene, and anti-GD2 introduced by BeiGene from EUSA Pharma.
-
Hengrui's Fluzoparib is approved for clinical treatment of colorectal cancer with bevacizumab
Time of Update: 2021-10-10
On September 28, Hengrui Medicine announced that the PARP inhibitor fluzoparib has been approved for a phase Ib/III clinical trial, combined with bevacizumab versus capecitabine and bevacizumab for unresectable or metastatic disease First-line maintenance treatment for colorectal cancer .
-
Why the rare disease market has become a "fragrance", attracting major pharmaceutical companies to compete for layout
Time of Update: 2021-10-10
In this regard, industry analysts believe that the reason why the rare disease market has attracted major pharmaceutical companies to vie for deployment is mainly because it has a lot of room for development to be explored .
-
Xinlitai "strikes" innovative drugs!
Time of Update: 2021-10-10
Sales of terminal GLP-1 agonists in public medical institutions in China (unit: ten thousand yuan)Source: Mi Nei. com, China's public medical institutions terminal competition patternIn recent years, license-in (authorized introduction) transactions in the domestic pharmaceutical market have been hot, and local pharmaceutical companies have taken this to quickly enter the innovative drug track and enrich their pipeline of products under research .
-
2 Qilu Class 1 biological drugs are coming!
Time of Update: 2021-10-10
On September 28, CDE's official website showed that Qilu Pharmaceutical's QLF32004 and QLP31907 injections for class 1 biological drug injections have obtained the implied license of clinical trials and are intended to be used for the treatment of advanced malignant solid tumors and B-cell malignant tumors .
-
The basic medical insurance for urban and rural residents will be insured from October
Time of Update: 2021-10-10
A reporter from Beijing Youth Daily noted that the "Announcement" made it clear that the time for applying for the basic medical insurance for urban and rural residents in this city in 2022 will be from October 1 to December 30, 2021, and the personal payment standard will be the same as in 2021 .
-
With the continued positive development of the pharmaceutical packaging industry, this type of enterprise has a broad market prospect
Time of Update: 2021-10-10
From the perspective of development trends, China is currently continuously introducing and upgrading pharmaceutical packaging equipment and materials, and the entire industry is showing a brand new situation .
-
Will taking antihypertensive drugs be resistant?
Time of Update: 2021-10-10
The blood pressure control of a certain drug is related to the patient's age, compliance, eating habits and other factors .
-
The three quarterly reports surfaced, which one in the pharmaceutical and biological industry is happy and which one is worried?
Time of Update: 2021-10-10
Yan'an Bikang said that the new energy products of Jiujiujiu Technology, its subsidiary, were affected by market demand, the release of production capacity, and the increase in market prices, resulting in an increase in profits over the same period last year, which played a positive role in promoting the company's performance growth .
-
In the future, where is the outlet for the development of the pharmaceutical and health industry?
Time of Update: 2021-10-10
According to data from the China Business Industry Research Institute, the size of China's pharmaceutical e-commerce market has increased from 95 billion yuan in 2016 to 199.
The China Business Industry Research Institute predicts that in 2021, the pharmaceutical e-commerce market under the B2B model in my country will reach 258.
-
Two pharmaceutical companies join forces to enter the drug market over 10 billion yuan
Time of Update: 2021-10-10
Taking the first marketed target PARP inhibitor for synthetic lethal therapy as an example, according to evaluate Pharma’s forecast, only four types (Olaparib, Niraparib, Niraparib, and Rucaparib) approved globally by 2020 will be considered.
